Medindia

X

Advanced Bionics Deploys CEVA-TeakLite(TM) DSP Core to Enhance Its Harmony(TM) HiResolution(R) Bionic Ear System

Wednesday, September 19, 2007 General News J E 4
Advertisement
SAN JOSE, Calif., Sept. 18 CEVA, Inc.(Nasdaq: CEVA; LSE: CVA), a leading licensor of innovative intellectualproperty (IP) platform solutions and DSP cores for wireless, consumer andmultimedia applications, today announced that Advanced Bionics has licensedand deployed the CEVA-TeakLite(TM) DSP core in its Harmony HiResolution BionicEar System.

(Logo: http://www.newscom.com/cgi-bin/prnh/20051010/CEVALOGO)

The CEVA-TeakLite core, used in the external (behind the ear) soundprocessor of the Harmony system, is a key component in providing unmatchedhearing capability for severe-to-profoundly deaf individuals that wouldotherwise have little or no perception of sound. The device benefits from theCEVA core's support for CD-quality audio, wide input dynamic range andpowerful dual-loop automatic gain control. This technology is used in theHarmony system, with its breakthrough HiRes Fidelity 120(TM) processingfeature, to help cochlear implant recipients appreciate music, use thetelephone, and hear in noisy environments, without having to make adjustmentsto their processor. The ultra-low power requirements of CEVA's mostwidely-deployed DSP core enables extended battery life so Harmony systemrecipients can use their processor all day on a single battery charge.

"We are very pleased to be working with Advanced Bionics and contributingto the sophisticated technology required for its state-of-the-art cochlearimplant system," said Gideon Wertheizer, CEO of CEVA. "Our CEVA-TeakLite DSPcore is ideally suited to meet the demanding requirements for these rugged,yet streamlined and intelligent low-power devices."

Advanced Bionics' high-tech, high-performance cochlear implant systemshelp maximize the hearing potential of people experiencing severe-to-profoundhearing loss (deafness), intended to provide a better quality of life forusers. The cochlear implant marketplace demands ever-increasing technicaladvances in order to address the needs of users ranging from young children toour growing aging population.

The CEVA-TeakLite is a broadly used general-purpose DSP core optimized forlow-power and high-performance digital signal processing applications. Thecore enables a large range of high-volume applications such as cellularhandsets, DVDs, disk drives, VoIP gateways, IP phones, mobile audio, as wellas hearing aid systems. The CEVA-TeakLite is a highly efficient low-powersingle MAC DSP core, measuring less than 0.2mm2 in a 90nm process, andutilizing an optimized 16-bit instruction set. The fully synthesizable,process-independent CEVA-TeakLite can be ported to any ASIC or foundry-baseddesigns.

About Advanced Bionics

Advanced Bionics, founded in 1993 by Alfred E. Mann, is a global leader inthe development of implantable technologies that improve the lives of hearingimpaired individuals. Headquartered in Valencia, California, Advanced Bionicsis the only American manufacturer of cochlear implants -- the only technologyapproved by the U.S. Food and Drug Administration (FDA) to restore a humansense.

About CEVA, Inc.

Headquartered in San Jose, Calif., CEVA is a leading licensor ofinnovative intellectual property (IP) platform solutions and DSP cores forwireless, consumer and multimedia applications. CEVA's IP portfolio includescomprehensive platform solutions for multimedia, audio, voice over packet(VoP), Bluetooth, Serial Attached SCSI (SAS) and Serial ATA (SATA), and a widerange of programmable DSP cores and subsystems with differentprice/performance metrics serving multiple markets. In 2006, CEVA's IP wasshipped in over 190 million devices.

For more information, visit www.ceva-dsp.com

SOURCE CEVA, Inc.
Advertisement


Advertisement

You May Also Like

Advertisement
View All

Post your Comments

Comments should be on the topic and should not be abusive. The editorial team reserves the right to review and moderate the comments posted on the site.
User Avatar
* Your comment can be maximum of 2500 characters
I agree to the terms and conditions
s
Phase 2 Clinical Studies Initiated for a Novel The...
S
DiObex Inc. to Present at BIO Mid-America Venture ...